Abstract
CD5-positive diffuse large B-cell lymphoma (CD5(+) DLBCL) is a rare immunophenotypic subtype of DLBCL, typically characterized by high aggressiveness, rapid disease progression, and poor prognosis. Even in the era of rituximab-based immunochemotherapy, survival benefits for these patients remain limited. In recent years, with the development of precision assessment tools such as genotyping and advances in research on personalized immunotargeted therapies, the understanding of CD5(+) DLBCL has deepened, offering the prospect of improved treatment outcomes for some patients. To further standardize diagnosis and treatment practices, the Lymphoid Disease Group, Chinese Society of Hematology, Chinese Medical Association and the Lymphoma Expert Committee of China Anti-Cancer Association have organized relevant experts to formulate this consensus, aiming to guide the standardized diagnosis and treatment of CD5(+) DLBCL patients in China.